The beneficial pharmacological effects and potential mechanisms of picroside II: Evidence of its benefits from in vitro and in vivo - 27/10/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 12 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | PII showed therapeutic potential in prevention and treatment of I/R injury, liver damage, inflammation and cancer. |
• | Various biological activities of PII have been widely demonstrated in many studies. |
• | PII may serve as a promising therapeutic agent for organic I/R injury prevention. |
Abstract |
Picrorhiza kurroa, the dried rhizome of Picrorhiza kurroa Royle ex Benth, is a famous Chinese herb that has been traditionally used in China. Picroside II (PII), a glycoside derivative, is the main bioactive constituent of Picrorhiza kurroa. In the past several decades, bioactive components from Picrorhiza kurroa have attracted the attention of researchers due to their promising therapeutic effects. A large number of studies have demonstrated the therapeutic potential of PII for the prevention and treatment of some diseases, such as organic ischemia/reperfusion (I/R) injury, liver damage, inflammation, cancer metastasis and angiogenesis. In the present paper, we aimed to provide an overview of the pharmacology of PII, focusing on its anti-oxidant, anti-inflammatory and anti-apoptotic activities. Meanwhile, the plant tissue distribution and pharmacokinetic properties were also described. Due to its beneficial pharmacological effects in I/R injury, PII may serve as a promising therapeutic agent for organic I/R injury prevention.
Le texte complet de cet article est disponible en PDF.Abbreviations : Act-D, AP, ANIT, ALT, AST, ALP, ALI, BALF, BBB, bFGF, CIV, CCA, CytC, CREB, CCI, CLP, D-GalN, dbcAMP, EAR, ECA, EndoG, FXR, GSH, GSH-Px, GSSG, GPT, γ-GT, H/R, HMGB1, HDM, I/R, LDH, LPS, MBP, mNSS, MLCK, mPTP, MDA, MMP, MPO, MCAO, NGF, NLRP3, OGD, PII, ROS, ROCK, SOD, SAP, TLR, TOS, TAS, TBA, TBIL, NSE, VDAC
Keywords : Picroside II, Anti-apoptosis, Anti-oxidant, Ischemia/reperfusion injury, Anti-inflammation, Pharmacokinetics
Plan
Vol 130
Article 110421- octobre 2020 Retour au numéro
Article précédent
- Editorial Board
- A review on the pharmacokinetics of paeoniflorin and its anti-inflammatory and immunomodulatory effects
- Yan-Xi Zhou, Xiao-Hong Gong, Hong Zhang, Cheng Peng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?